CIK 0001404644 · Non-accelerated filer<br>Smaller reporting company
Neurogene Inc.
Sign in to watch- Ticker
- NGNE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 980542593
- Phone
- (877) 237-5020
- Business address
- 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-22 | McMinn Rachel Chief Executive Officer | Option exercise | +756 | $25.32 | $19K | 1,345,063 |
| 2026-09-22 | McMinn Rachel Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −756 | 0 | ||
| 2026-07-07 | Cvijic Christine Mikail President and CFO | Sale 10b5-1 | −4,200 | $36.13 | $152K | 84,040 |
| 2026-07-06 | Cvijic Christine Mikail President and CFO | Sale 10b5-1 | −600 | $36.02 | $22K | 88,240 |
| 2026-07-02 | Cvijic Christine Mikail President and CFO | Sale 10b5-1 | −2,531 | $34.58 | $88K | 90,370 |
| 2026-07-02 | Cvijic Christine Mikail President and CFO | Sale 10b5-1 | −1,530 | $35.23 | $54K | 88,840 |
| 2026-07-01 | Cvijic Christine Mikail President and CFO | Sale 10b5-1 | −739 | $34.06 | $25K | 92,901 |
| 2026-05-06 | Cvijic Christine Mikail President and CFO | Sale 10b5-1 | −4,800 | $30.07 | $144K | 98,440 |
| 2026-05-06 | Cvijic Christine Mikail President and CFO | Sale 10b5-1 | −4,800 | $32.44 | $156K | 93,640 |
| 2026-05-05 | Shafer Christina Chief Commercial Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2026-03-26 | Jordan Julie Chief Medical Officer | Sale 10b5-1 | −828 | $21.89 | $18K | 12,472 |
| 2026-03-26 | McMinn Rachel Chief Executive Officer | Sale 10b5-1 | −3,352 | $22.07 | $74K | 1,344,307 |
| 2026-03-26 | Cvijic Christine Mikail President and CFO | Sale 10b5-1 | −2,558 | $21.62 | $55K | 103,240 |
| 2026-03-13 | Cobb Stuart Chief Scientific Officer | Sale 10b5-1 | −3,991 | $20.41 | $81K | 33,303 |
| 2026-03-13 | Cobb Stuart Chief Scientific Officer | Sale 10b5-1 | −2,658 | $21.34 | $57K | 30,645 |
| 2026-03-13 | Cobb Stuart Chief Scientific Officer | Sale 10b5-1 | −148 | $22.08 | $3K | 30,497 |
| 2026-03-13 | Cvijic Christine Mikail President and CFO | Sale 10b5-1 | −2,387 | $20.42 | $49K | 107,456 |
| 2026-03-13 | Cvijic Christine Mikail President and CFO | Sale 10b5-1 | −1,395 | $21.25 | $30K | 106,061 |
| 2026-03-13 | Cvijic Christine Mikail President and CFO | Sale 10b5-1 | −263 | $22.02 | $6K | 105,798 |
| 2026-02-27 | Cvijic Christine Mikail President and CFO | Sale 10b5-1 | −4,800 | $25.11 | $121K | 109,843 |
Page 1 of 8 · 158 trades